1. Home
  2. AKBA vs EZPW Comparison

AKBA vs EZPW Comparison

Compare AKBA & EZPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • EZPW
  • Stock Information
  • Founded
  • AKBA 2007
  • EZPW 1989
  • Country
  • AKBA United States
  • EZPW United States
  • Employees
  • AKBA N/A
  • EZPW N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • EZPW Other Specialty Stores
  • Sector
  • AKBA Health Care
  • EZPW Consumer Discretionary
  • Exchange
  • AKBA Nasdaq
  • EZPW Nasdaq
  • Market Cap
  • AKBA 958.6M
  • EZPW 814.0M
  • IPO Year
  • AKBA 2014
  • EZPW 1991
  • Fundamental
  • Price
  • AKBA $3.69
  • EZPW $13.49
  • Analyst Decision
  • AKBA Strong Buy
  • EZPW Strong Buy
  • Analyst Count
  • AKBA 5
  • EZPW 3
  • Target Price
  • AKBA $6.90
  • EZPW $19.00
  • AVG Volume (30 Days)
  • AKBA 6.6M
  • EZPW 888.8K
  • Earning Date
  • AKBA 08-07-2025
  • EZPW 07-30-2025
  • Dividend Yield
  • AKBA N/A
  • EZPW N/A
  • EPS Growth
  • AKBA N/A
  • EZPW 18.94
  • EPS
  • AKBA N/A
  • EZPW 1.19
  • Revenue
  • AKBA $184,909,000.00
  • EZPW $1,202,458,000.00
  • Revenue This Year
  • AKBA $26.88
  • EZPW $9.25
  • Revenue Next Year
  • AKBA $44.34
  • EZPW $6.38
  • P/E Ratio
  • AKBA N/A
  • EZPW $11.31
  • Revenue Growth
  • AKBA N/A
  • EZPW 8.14
  • 52 Week Low
  • AKBA $0.80
  • EZPW $9.66
  • 52 Week High
  • AKBA $4.08
  • EZPW $16.60
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 63.96
  • EZPW 46.00
  • Support Level
  • AKBA $3.56
  • EZPW $12.89
  • Resistance Level
  • AKBA $3.87
  • EZPW $13.67
  • Average True Range (ATR)
  • AKBA 0.22
  • EZPW 0.34
  • MACD
  • AKBA -0.04
  • EZPW 0.07
  • Stochastic Oscillator
  • AKBA 36.53
  • EZPW 51.82

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About EZPW EZCORP Inc. Non Voting

EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.

Share on Social Networks: